SFJ XII (Nektar)

SFJ and Nektar agreed to co-developing Bempeg (IL-2) in a phase 3 clinical study in head and neck cancer in a clinical co-development deal. The investment entity for this was SFJ XII. Nektar subsequently discontinued all Bempeg studies due to failures in two other partnered indications. As a result, SFJ XII ceased funding and was wound down early.